文献类型：期刊文献

中文题名：阿加曲班研究进展

英文题名：Research progress of argatroban

作者：张子彦（综述）[1];张宏卫（审校）[1]

机构：[1]绍兴文理学院医学院附属医院,浙江绍兴312000

年份：2007

卷号：34

期号：8

起止页码：483

中文期刊名：国际内科学杂志

外文期刊名：International Journal of Internal Medicine

语种：中文

中文关键词：阿加曲班;肝素诱导的血小板减少及血栓症;缺血性脑卒中;经皮冠状动脉介入

外文关键词：Argatroban; Heparin-induced thrombocytopenia and thrombosis syndrome; Ischemic stroke; Percutaneous coronary intervention

中文摘要：阿加曲班是合成的小分子药物，为一价直接凝血酶抑制剂，阿加曲班直接与凝血酶的催化活性位点结合，不但灭活液相凝血酶，还能够灭活与纤维蛋白血栓结合的凝血酶，目前已批准用于肝素诱导的血小板减少及血栓症、经皮冠状动脉介入治疗、脑卒中溶栓等血栓性疾病。体内外研究表明，它还抑制凝血酶的其他作用，如可以抑制肿瘤转移、炎症过程及血管成形术后的再狭窄等。

外文摘要：Argatroban is a synthetic small molecule and a univalent direct thrombin inhibitor. It hinds to the catalytic site of the thrombin. It＇s able to inhibit both free and colt-bound thrombin. Argatroban was approved to used in heparin-induced thrombocytopenia and thrombosis syndrome, pereutaneous coronary intervention, acute cerebral stroke and so on. In vitro, argatroban could inhibit other roles of thrombin, such as tumor cell metastasis, inflammation and restenosis after angioplasty.